Activation of the Tubulo-Glomerular Feedback by SGLT2 Inhibitors in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease: Toward the End of a Myth?

Diabetes Care. 2022 Oct 1;45(10):e148-e149. doi: 10.2337/dc22-0921.

Authors

Alexandre O Gérard^{1

2}, Audrey Laurain¹, Guillaume Favre¹, Milou-Daniel Drici², Vincent L M Esnault¹

Affiliations

¹ Nephrology-Dialysis-Transplantation Department, Pasteur Hospital, Université Côte d'Azur, Nice, France.
² Pharmacology Department, Pasteur Hospital, Université Côte d'Azur, Nice, France.

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Feedback
Glomerular Filtration Rate / physiology
Humans
Kidney
Kidney Glomerulus
Renal Insufficiency, Chronic* / drug therapy
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors